Stem cells can restore the entire hematopoietic system, but the details of the signals and growth factors involved are not fully understood. We offer stem cells from several different sources so you can study differentiation using the source that matches your interests.
Cord blood mononuclear cells have two interesting features: there are more stem cells present than in normal blood (1%) and because the cells are from the baby, there are more naïve T cells and B cells than in adult samples. Our cord blood mononuclear cells are purified from umbilical cord blood by density gradient centrifugation and characterized for their CD34+ cell content.
Cord blood CD34+ cells typically make up about 1% of the mononuclear cells found in umbilical cord blood. Our CD34+ stem cells from cord blood are isolated by positive immunomagnetic selection and tested for purity and viability. CD34+ cells are pluripotent stem cells that give rise to all cell types in blood. Less than 1% of nucleated cells in the blood are CD34+. These stem cells are typically found in bone marrow but are also found in peripheral blood and cord blood. We have CD34+ stem cells from all three sources. All donors are tested for blood-borne pathogens and are negative for HIV-1, HIV-2, Hepatitis B, and Hepatitis C.
Bone marrow CD34+ cells are isolated by positive immunomagnetic selection and tested for purity and viability. All donors are tested for blood-borne pathogens and are negative for HIV-1, HIV-2, Hepatitis B, and Hepatitis C.
Mesencyhmal stromal cells can be differentiated into adipocytes (fat cells), osteoblasts (bone cells), chondroblasts (cartilage cells), or myocytes (muscle cells) in vitro. Many therapeutic applications have been proposed using mesenchymal stromal cells primarily for tissue repair. These bone marrow-derived stem cell products are collected from individual donors rather than pooled populations, and harvested from the primary culture and then frozen.
Mobilized PBMC are from healthy donors given granulocyte colony stimulating factor (G-CSF). Mobilized PBMC contain higher proportions of CD34+ than untreated PBMC. Flow cytometric analysis is provided for each lot. Peripheral blood hematopoietic stem cells from donors treated with G-CSF have largely replaced bone marrow for transplantation purposes. Administration of G-CSF stimulates hematopoietic stem cells to mobilize from the bone marrow to the peripheral blood. We offer PBMC from healthy donors treated with G-CSF. These mobilized PBMC contain a higher proportion of CD34+ cells than untreated PBMC. Flow cytometric analysis is provided for each lot.
Mobilized CD34+ cells are isolated from mobilized PBMC using immunomagnetic cell isolation. These represent the cells that repopulate the hematopoietic system following transplantation. Bone marrow transplantation is now performed using PBMC from donors treated with G-CSF. This treatment stimulates CD34+ cells and other immature cells to move into the circulation where they can easily be collected. We isolate CD34+ cells by positive immunomagnetic selection. Try these in your studies of hematopoietic cell differentiation.